199 related articles for article (PubMed ID: 32394054)
41. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
42. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
43. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Eur J Cancer; 1998 Jul; 34(8):1193-7. PubMed ID: 9849478
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
45. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
46. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract][Full Text] [Related]
47. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
Kulwas A; Lisewska B; Jundziłł W; Ruszkowska B; Drewniak W; Ruprecht Z; Gadomska G; Rość D
Adv Med Sci; 2017 Mar; 62(1):87-91. PubMed ID: 28193577
[TBL] [Abstract][Full Text] [Related]
48. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
49. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
50. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
51. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC; Yao JS
J Vasc Surg; 1996 Nov; 24(5):719-24. PubMed ID: 8918314
[TBL] [Abstract][Full Text] [Related]
52. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
53. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
[TBL] [Abstract][Full Text] [Related]
54. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma.
Dobrzycka B; Mackowiak-Matejczyk B; Kinalski M; Terlikowski SJ
Gynecol Oncol; 2013 Mar; 128(3):454-60. PubMed ID: 23206584
[TBL] [Abstract][Full Text] [Related]
55. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
56. Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma.
Salmaggi A; Croci D; Prina P; Cajola L; Pollo B; Marras CE; Ciusani E; Silvani A; Boiardi A; Sciacca FL
Cancer Biol Ther; 2006 Feb; 5(2):204-9. PubMed ID: 16357523
[TBL] [Abstract][Full Text] [Related]
57. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
58. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
59. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
[TBL] [Abstract][Full Text] [Related]
60. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Chambers SK; Ivins CM; Carcangiu ML
Int J Cancer; 1998 Oct; 79(5):449-54. PubMed ID: 9761111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
